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Positron Emission Tomography Score Has Greater
Prognostic Significance Than Pretreatment Risk
Stratification in Early-Stage Hodgkin Lymphoma
in the UK RAPID Study
Sally F. Barrington, MSc, MD1; Elizabeth H. Phillips, MBBS2; Nicholas Counsell, MSc2; Barry Hancock, MD3; Ruth Pettengell, PhD4;
Peter Johnson, MD5; William Townsend, MD6; Dominic Culligan, MD7; Bilyana Popova, MSc2; Laura Clifton-Hadley, PhD2;
Andrew McMillan, PhD8; Peter Hoskin, PhD9,10; Michael J. O’Doherty, MA, MSc, MD1; Tim Illidge, MD, PhD10; and John Radford, MD10
abstract
PURPOSE Accurate stratification of patients is an important goal in Hodgkin lymphoma (HL), but the role of
pretreatment clinical risk stratification in the context of positron emission tomography (PET) –adapted treatment
is unclear. We performed a subsidiary analysis of the RAPID trial to assess the prognostic value of pretreatment
risk factors and PET score in determining outcomes.
PATIENTS AND METHODS Patients with stage IA to IIA HL and no mediastinal bulk underwent PET assessment
after three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine; 143 PET-positive patients (PET
score, 3 to 5) received a fourth doxorubicin, bleomycin, vinblastine, and dacarbazine cycle and involved-field
radiotherapy, and 419 patients in complete metabolic remission were randomly assigned to receive involved-
field radiotherapy (n = 208) or no additional treatment (n = 211). Cox regression was used to investigate the
association between PET score and pretreatment risk factors with HL-specific event-free survival (EFS).
RESULTS High PET score was associated with inferior EFS, before (P, .001) and after adjustment (P = .01) for
baseline risk stratification. Only patients with a postchemotherapy PET score of 5 (uptake $ three times
maximum liver uptake) had an increased risk of progression or HL-related death (hazard ratio, 9.4 v score of 3;
95% CI, 2.8 to 31.3 and hazard ratio, 6.7 v score of 4; 95% CI, 1.4 to 31.7). Patients with a PET score of 5 also
had inferior progression-free and overall survival. There was no association between European Organisation for
Research and Treatment of Cancer or German Hodgkin Study Group risk group and EFS, before or after
adjusting for PET score (all P . .4).
CONCLUSION In RAPID, a positive PET scan did not carry uniform prognostic weight; only a PET score of 5 was
associated with inferior outcomes. This suggests that in future trials involving patients without B symptoms or
mediastinal bulk, a score of 5 rather than a positive PET result should be used to guide treatment escalation in
early-stage HL.
J Clin Oncol 37. © 2019 by American Society of Clinical Oncology
INTRODUCTION
The goal of Hodgkin lymphoma (HL) treatment is to
optimize patient outcomes by maximizing cure while
minimizing toxicity. Cure rates for early-stage HL are
high, but treatment toxicity reduces long-term survival
and confers significant morbidity.1,2 Risk-adapted
treatment strategies can potentially address this but
are reliant on accurate risk stratification of patients
to facilitate individualized treatment approaches. The
German Hodgkin Study Group (GHSG) and the Eu-
ropean Organisation for Research and Treatment
of Cancer (EORTC) have developed clinical prognostic
scores for early-stage HL that are frequently used
to risk stratify patients for treatment selection,3-5 but it
is unclear whether these scores have sufficient
specificity to predict outcomes with modern combined-
modality treatment.6
Over the past decade, early response to treatment
assessed by [18F]fluorodeoxyglucose (FDG) positron
emission tomography (PET) has emerged as a pow-
erful prognostic indicator in HL.7,8 PET-guided ap-
proaches have been evaluated in trials9-13 and
successfully implemented in clinical practice,14 as one
of the first applications of personalized medicine. The
introduction of the 5-point scale for PET reporting
helped to standardize image interpretation15 and
allowed the threshold used to define a positive PET
scan to be adapted according to the research ques-
tion.16 In trials involving patients with HL, a positive
PET scan has been defined as either FDG uptake
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greater than the normal mediastinum (PET score, 3, 4, or 5)
or equal to or greater than the liver uptake (score, 4 or 5),
partly dependent on whether the study intervention involves
treatment escalation or de-escalation.16 Little is known
about the predictive value of individual PET scores, and
it remains unclear whether all PET-positive or -negative
patients derive equal benefit from PET-adapted
approaches.17
The randomized H10 study demonstrated that patients with
early-stage HL with a positive PET scan after two cycles of
doxorubicin, bleomycin, vinblastine, and dacarbazine
(ABVD) benefit from treatment intensification.9 Patients
with positive PET scans had a progression-free survival
(PFS) advantage when switched to escalated bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisone (escBEACOPP), compared
with continuing ABVD, although they experienced greater
toxicity. PET positivity in H10 was defined by International
Harmonization Project (IHP) criteria (broadly equivalent to
PET scores of 3, 4, or 518), and it is unknown whether all
patients with a PET score of 3 or higher derive equal benefit
from treatment escalation. We performed this subsidiary
analysis of the United Kingdom (UK) National Cancer
Research Institute (NCRI) RAPID (Randomised Phase III
Trial to Determine the Role of FDG-PET Imaging in Clinical
Stages IA/IIA Hodgkin’s Disease) study,11 in which all PET-
positive patients continued ABVD, to explore whether
a subset of PET-positive patients with early-stage HL could
be adequately treated with ABVD and radiotherapy. Our
aim was to investigate the associations of PET score after
three cycles of ABVD, pretreatment risk factors, and clinical
prognostic scores with patient outcomes.
PATIENTS AND METHODS
Study Design
The RAPID trial was one of the first to use a PET-adapted
treatment approach in early-stage HL.11 The primary ob-
jective of this phase III noninferiority study was to in-
vestigate whether PET response could be used to omit
radiotherapy in selected patients and reduce late toxicity.
The trial design and randomization procedures have been
published.11 In brief, patients with newly diagnosed, his-
tologically confirmed stage IA or IIA HL were eligible if age
16 to 75 years and without mediastinal bulk disease.
Patients screened
(N = 602)
Excluded                                  (n = 34)
   Ineligible and withdrawn                        (n = 8)
   Did not have PET scan:                      (n = 26)
      Withdrew consent                         (n = 11)
      Did not complete three cycles of ABVD  (n = 8)
      Technical issues with PET scanner          (n = 3)
      Died                            (n = 2)
      Disease progression                                  (n = 1)
      Unknown reason                      (n = 1)
PET assessment after three
cycles of ABVD 
(n = 568)
Were not randomly           (n = 6)
assigned:
   Withdrew consent          (n = 3)
   Withdrawn by clinician  (n = 2)
   Error                               (n = 1)
Randomly assigned                     (n = 419)
   NFT                    (n = 211)
   IFRT                                    (n = 208)
Included in study
(n = 562)
PET positive
(n = 143)
Achieved CMR 
(n = 425)
FIG 1. CONSORT dia-
gram. ABVD, doxorubicin,
bleomycin, vinblastine,
and dacarbazine; CMR,
complete metabolic re-
sponse; IFRT, involved-
field radiotherapy; NFT,
no further treatment;
PET, positron emission
tomography.
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Baseline staging was performed by computed tomography
(CT). Clinical risk stratification was retrospectively assessed
according to standard criteria (Appendix Table A1, online
only).
Patients received three cycles of ABVD and then underwent
PET and CT assessment. Patients with progressive disease
by CT criteria were excluded at this point.19 PET scans were
performed within UK NCRI-accredited PET centers using
standardized methods for quality control and image ac-
quisition.20 PET images were centrally reviewed by two
independent reporters at St Thomas’ Hospital, London,
United Kingdom. FDG uptake was prospectively graded
using a 5-point scale according to the likelihood of disease
response or nonresponse. The central review score de-
termined further management. A similar graded response
method was subsequently adopted internationally, widely
referred to as the Deauville criteria.15,21 A PET score of 5
was defined as 3 or more times the maximum liver uptake
in RAPID, and uptake greater than the mediastinum was
considered to represent a positive PET result.
In total, 602 patients were recruited between October 2003
and August 2010, of whom 571 completed three cycles of
ABVD and underwent PET evaluation; 145 patients
(25.4%) were PET positive (uptake $ mediastinum; PET
score, 3, 4, or 5) and received a fourth cycle of ABVD and
30 Gy of involved-field radiotherapy (IFRT); 426 patients
(74.6%) achieved complete metabolic response (CMR;
PET score, 1 or 2) and were randomly assigned using
a one-to-one ratio to receive 30-Gy IFRT (n = 209) or no
additional treatment (NFT; n = 211). Six patients with CMR
withdrew before random assignment. Three additional
patients were excluded from this analysis, where review of
original diagnostic material at relapse identified a non-HL
diagnosis. Outcomes for 562 patients are reported here
(PET positive, n = 143; IFRT, n = 208; NFT, n = 211; Fig 1).
Patients were monitored for disease progression by regular
clinical evaluation and by CT scans at 6, 12, and 24months
post-treatment.
Statistical Considerations
The primary end point of this subsidiary analysis was HL-
specific event-free survival (EFS), calculated from the date
of registration to relapse or death resulting from HL, cen-
sored at the date last seen or date of death resulting from
any non-HL cause. PFS was calculated from the date of
registration to relapse or death resulting from any cause,
censored at the date last seen. Overall survival (OS) was
calculated from the date of registration to death resulting
from any cause, censored at the date last seen.
EFS, PFS, and OS are described using the Kaplan-Meier
method; univariable and multivariable Cox regression an-
alyses were performed to explore the associations with PET
score, pretreatment risk factors, and clinical prognostic
scores.
RESULTS
Baseline characteristics are listed in Table 1; data for risk
stratification by GHSG criteria were available for 480 pa-
tients (85.4%), of whom 155 (32.3%) had unfavorable risk.
Data for stratification by EORTC criteria were available for
492 patients (87.5%), of whom 184 (37.4%) were un-
favorable risk. Patients were classified as unfavorable risk
TABLE 1. Baseline Demographic and Clinical Characteristics (N = 562)
Characteristic
No. (%)
PET Negative
PET Positive
(n = 143)
IFRT
(n = 208)
NFT
(n = 211)
Age, years
Median 34 34 36
Range 16-74 16-75 18-75
, 50 160 (76.9) 166 (78.7) 103 (72.0)
$ 50 48 (23.1) 45 (21.3) 40 (28.0)
Sex
Female 106 (51.0) 104 (49.3) 49 (34.3)
Male 102 (49.0) 107 (50.7) 94 (65.7)
Stage
IA 69 (33.2) 70 (33.2) 46 (32.2)
IIA 139 (66.8) 141 (66.8) 97 (67.8)
ESR $ 50 (n = 468) 20 (11.8) 22 (12.1) 19 (16.4)
Nonmediastinal bulk present 2 (1.0) 1 (0.5) 3 (2.1)
Extranodal disease present 0 1 (0.5) 0
No. of involved nodal sites
$ 3 64 (30.8) 61 (28.9) 50 (35.0)
$ 4 19 (9.1) 22 (10.4) 15 (10.5)
GHSG criteria (n = 480)
Favorable 114 (65.1) 136 (73.9) 75 (62.0)
Unfavorable 61 (34.9) 48 (26.1) 46 (38.0)
Missing 33 27 22
EORTC criteria (n = 492)
Favorable 118 (64.5) 122 (65.9) 68 (54.8)
Unfavorable 65 (35.5) 63 (34.1) 56 (45.2)
Missing 25 26 19
PET score
1 141 (67.8) 157 (74.4) 0
2 67 (32.2) 54 (25.6) 0
3 0 0 90 (62.9)
4 0 0 32 (22.4)
5 0 0 21 (14.7)
Abbreviations: EORTC, European Organisation for Research and Treatment of
Cancer; ESR, erythrocyte sedimentation rate; GHSG, German Hodgkin Study
Group; IFRT, involved-field radiotherapy; NFT, no further treatment; PET, positron
emission tomography.
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largely because of the number of involved nodal sites,
age (EORTC only), and erythrocyte sedimentation rate; only
one patient had extranodal disease, and patients with
mediastinal bulk and B symptoms were excluded from
RAPID.
After a median follow-up of 61.6 months, 44 patients
(7.8%) had an HL-related event, with five deaths resulting
from HL and 39 additional disease progressions. Twelve
non-HL deaths occurred from pneumonia or pneumonitis
related to primary HL treatment (n = 6), other malignancies
(n = 4), myocardial fibrosis (n = 1), and intracranial
hemorrhage (n = 1). For PET-positive patients, there was no
end-of-treatment PET scan; however, no patient received
salvage therapy for inadequate response in the absence of
confirmed disease progression.
Outcomes by Treatment Arm
EFS was 89.7% (95% CI, 84.6% to 94.8%) at 5 years in the
PET-positive group and 93.0% (95% CI, 90.5% to 95.5%)
in the PET-negative group (IFRT arm: 96.0%; 95% CI,
93.1% to 98.9%; NFT arm: 90.1%; 95% CI, 85.8% to
94.4%). There was no difference in EFS between patients
achieving CMR, who received three cycles of ABVD with or
without IFRT, and PET-positive patients treated with four
cycles of ABVD and IFRT (hazard ratio [HR], 0.68; 95% CI,
0.36 to 1.29; P = .24). There was an improvement in EFS
for patients achieving CMR randomly assigned to receive
IFRT compared with PET-positive patients (HR, 0.40; 95%
CI, 0.17 to 0.93; P = .03) but not for those randomly
assigned to receive NFT compared with PET-positive pa-
tients (HR, 0.98; 95% CI, 0.50 to 1.93; P = .95). Similar but
nonsignificant results were observed for PFS.
There was better discrimination between PET-positive and
-negative patients in terms of both EFS and PFS using the
Lugano classification of PET positivity (PET score, 4 or 5;
liver threshold) than the mediastinal threshold.21 Patients
with a PET score of 4 or 5 had a 5-year EFS of 80.3% (95%
CI, 69.3% to 91.3%).
Outcomes According to PET Score After Three Cycles
of ABVD
There was strong evidence that higher PET score was
associated with increased risk of progression or HL-related
death (EFS; P , .001) on univariable analysis, and results
remained significant, with similar effect sizes, when ad-
justed for baseline GHSG (P = .01) or EORTC risk strati-
fication (P = .01). A similar association was identified
between PET score and PFS (unadjusted P , .001; ad-
justed P = .03 and P = .04 for GHSG and EORTC strati-
fication, respectively).
EFS and PFS by individual PET score are listed in Table 2
and Figures 2A and 2B. Patients with a score of 5 had
a significantly higher risk of progression or HL-related death
than those with all other PET scores (Table 3; P , .001 for
both EFS and PFS). Furthermore, a score of 5 identified
poor-prognosis patients among the favorable EORTC or
GHSG groups, and similarly, a lower PET score identified
good-prognosis patients in the unfavorable group (Ap-
pendix Figs A1A to A1D, online only). A similar association
was observed for OS (P = .002; Fig 2C). The 5-year OS rate
was 85.2% (95% CI, 69.7% to 100%) in patients with
a score of 5, compared with 97.8% (95% CI, 96.4% to
99.2%) in patients with a score of 1 to 4. Compared with
those with a score of 1 to 4, patients with a score of 5 were
TABLE 2. Events and 5-Year EFS and PFS Estimates According to PET Score After Three Cycles of ABVD and Pretreatment Risk Stratification
Risk Stratum No. of Patients
No. of Events (%) % (95% CI, %)
HL Relapse HL-Related Death Non–HL-Related Death 5-Year EFS 5-Year PFS
PET score
1 298 20 (6.7)* 0 (0.0) 9 (3.0)* 93.4 (90.5 to 96.3) 91.5 (88.2 to 94.8)
2 121 9 (7.4) 1 (0.8) 1 (0.8) 91.8 (86.1 to 97.5) 91.1 (85.2 to 97.0)
3 90 3 (3.3) 1 (1.1) 0 (0.0) 95.3 (90.8 to 99.8) 95.3 (90.8 to 99.8)
4 32 2 (6.3) 0 (0.0) 2 (6.3) 93.5 (84.9 to 100) 87.5 (76.1 to 98.9)
5 21 5 (23.8) 3 (14.3) 0 (0.0) 61.9 (41.1 to 82.7) 61.9 (41.1 to 82.7)
EORTC
Favorable 308 25 (8.1) 1 (0.3) 1 (0.3) 91.7 (88.6 to 94.8) 91.4 (88.1 to 94.7)
Unfavorable 184 10 (5.4)* 4 (2.2) 11 (6.0)* 91.4 (86.7 to 96.1) 87.3 (82.0 to 92.6)
GHSG
Favorable 325 25 (7.7)* 4 (1.2) 6 (1.8)* 90.8 (87.5 to 94.1) 89.9 (86.4 to 93.4)
Unfavorable 155 10 (6.5) 1 (0.6) 5 (3.2) 92.8 (88.5 to 97.1) 89.7 (84.8 to 94.6)
Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; EFS, event-free survival; EORTC, European Organisation for
Research and Treatment of Cancer; GHSG, German Hodgkin Study Group; HL, Hodgkin lymphoma; PET, positron emission tomography; PFS,
progression-free survival.
*One patient is included in both HL relapse and non–HL-related death categories.
4 © 2019 by American Society of Clinical Oncology
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more likely to bemale (76.2% v 53.0%; P = .04) and have 3
or more involved nodal sites (52.4% v 30.3%; P = .05), but
there was a similar proportion of patients with unfavorable
risk disease (Appendix Table A2, online only). Excluding
patients with a PET score of 5, there was no evidence of
pairwise differences between any other PET scores for EFS
or PFS.
Outcomes According to Pretreatment Risk Stratification
There was no evidence of an association between baseline
GHSG (HR, 1.26; 95% CI, 0.63 to 2.53; P = .51) or EORTC
(HR, 1.06; 95% CI, 0.56 to 2.04; P = .85) risk group and
EFS on univariable analysis (Table 3) or after adjusting for
PET score (GHSG: HR, 1.31; 95% CI, 0.65 to 2.62; P = .45;
EORTC: HR, 1.19; 95% CI, 0.61 to 2.29; P = .61). Survival
curves according to risk stratification are shown in Figures
3A and 3B. There were also no strong associations between
any individual pretreatment clinical risk factors and EFS,
although age was associated with PFS (Table 4), with 11 of
12 non-HL deaths occurring in patients age 50 years or
older. There was no evidence of an association between
baseline risk stratification and PFS, even though age
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FIG 2. Kaplan-Meier curves of (A) event-free survival (EFS), (B) progression-free survival (PFS), and (C) overall survival (OS) by positron emission
tomography (PET) score.
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50 years or older is an unfavorable risk factor according to
EORTC risk stratification.
DISCUSSION
The RAPID trial was a large prospective phase III ran-
domized study and the first to our knowledge to use
a graded 5-point scale for response adaptation in lym-
phoma, which has become the modern standard for re-
sponse assessment.16,21 Contemporaneous studies used
the now outdated IHP18 criteria, with binary positive versus
negative outcomes. This subsidiary analysis from RAPID
assessed the prognostic relevance of early PET, using
graded response and pretreatment risk factors in early-
stage HL. Our results demonstrate that PET score after
three cycles of ABVD has greater prognostic value than
pretreatment risk stratification. These findings support the
continuing use of early PET response assessment as part of
risk-adapted treatment strategies for early-stage HL.
Using a binary definition of PET positivity (score, 3 to 5) did
not sufficiently discriminate outcomes in RAPID. PET-
positive patients had a 5-year PFS of 88.4% (95% CI,
83.1% to 93.7%), compared with 91.4% (95% CI, 88.5%
to 94.3%) in those achieving CMR, although the two groups
had divergent treatment strategies. Some authors have
interpreted the results of RAPID and similar studies to mean
that PET assessment has limited prognostic value in early-
stage HL.22,23 However, the value of a positive PET scan is
dependent on the threshold used. Our results demonstrate
that individual PET scores are strongly associated with
outcomes and reinforce the role of PET in individualized
treatment planning in early-stage HL. Using the more
widely accepted definition of PET positivity in the Lugano
classification (score, 4 or 5)21 provided better discrimina-
tion, although only a score of 5 was clearly associated with
adverse outcomes in RAPID.
In RAPID, patients with a PET score of 3 had excellent
outcomes after ABVD and IFRT without chemotherapy
intensification. With a 5-year EFS of 95.3% (95% CI, 90.8%
to 99.8%) with ABVD and IFRT alone, our results do not
support treatment escalation in this cohort. Whether these
patients can be treated with ABVD alone remains unclear;
in the PET-adapted Cancer and Leukemia Group B
(CALGB) 50604 study, patients with a Deauville score of 3
had inferior outcomes to those with a score of 1 or 2 after
receiving four cycles of ABVD alone, although patient
numbers were small.12
Patients with a score of 4 also had good outcomes with
ABVD and IFRT, with a 5-year EFS of 93.5% (95% CI,
84.9% to 100%), similar to patients with a score of 1 to 3.
Although PFS was slightly lower in patients with a score of 4
(87.5%; 95% CI, 76.1% to 98.9%), this included two
treatment-related non-HL deaths (bronchopneumonia and
pneumonitis), where treatment escalation would not have
been beneficial or feasible. None of the deaths in this group
were attributable to HL.
Patients with a PET score of 5 after three cycles of ABVD
had particularly poor outcomes, with five progressions and
three HL-related deaths in only 21 patients. It is clear that
treatment with ABVD and IFRT alone is inadequate for
these patients, and alternative strategies should be
TABLE 3. EFS and PFS by PET Score: Unadjusted and Adjusted for Pretreatment Risk Stratification
PET Score Comparison
EFS PFS
HR (95% CI) P HR (95% CI) P
Unadjusted
5 v 1 6.79 (2.98 to 15.45) , .001 4.79 (2.18 to 10.54) , .001
5 v 2 4.96 (1.96 to 12.58) .001 4.47 (1.79 to 11.11) .001
5 v 3 9.43 (2.84 to 31.33) , .001 9.29 (2.80 to 30.87) , .001
5 v 4 6.72 (1.43 to 31.67) .016 3.35 (1.01 to 11.12) .049
Adjusted for GHSG
5 v 1 5.98 (2.49 to 14.36) , .001 4.02 (1.74 to 9.28) .001
5 v 2 4.39 (1.63 to 11.81) .003 4.29 (1.60 to 11.53) .004
5 v 3 7.03 (2.06 to 24.03) .002 6.91 (2.02 to 23.62) .002
5 v 4 4.92 (1.02 to 23.73) .047 2.43 (0.71 to 8.30) .158
Adjusted for EORTC
5 v 1 6.16 (2.54 to 14.91) , .001 3.79 (1.63 to 8.80) .002
5 v 2 4.57 (1.69 to 12.33) .003 3.72 (1.41 to 9.82) .008
5 v 3 7.39 (2.15 to 25.36) .001 6.73 (1.96 to 23.05) .002
5 v 4 5.19 (1.08 to 25.00) .040 2.57 (0.75 to 8.79) .132
Abbreviations: EFS, event-free survival; EORTC, European Organisation for Research and Treatment of Cancer; GHSG, GermanHodgkin Study
Group; HR, hazard ratio; PET, positron emission tomography; PFS, progression-free survival.
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explored. These might include escalation of chemotherapy
intensity, as demonstrated by the H10 study,9 or in-
troduction of novel agents.
One of the main limitations of this study is that relatively few
patients had a PET score of 4, with a small number of
events. Although our findings require additional confir-
mation, they are supported by emerging data in HL and
other lymphoma subtypes that demonstrate patients with
a PET score of 5 have significantly worse outcomes than
those with a PET score of 4.10,24-27 Baseline PET scans were
not performed; therefore, we cannot determine whether
patients with a score of 5 had appearances suggestive of
progressive metabolic disease, which may have a worse
prognosis. However, there was no evidence of progression
by CT criteria for patients in this analysis, and early pro-
gression is rare in early-stage HL.28 In other studies10,27 and
international guidance,16 a score of 5 refers to uptake
markedly above liver, without distinguishing whether
findings also suggest disease progression, such as in-
creasing metabolic activity and/or new lesions. There was
no formal monitoring of the discrepancy rate among central
PET reviewers, but several studies have demonstrated that
concordance between PET readers using the 5-point scale
is high (76% to 84%).8,29,30
It is unclear whether the results of the H10 study can be
generalized to the RAPID population, given significant
differences in inclusion criteria, particularly with respect to
B symptoms and mediastinal bulk. PET scans were also
performed earlier in H10, after two cycles of ABVD.
However, it is notable that, although H10 was randomized,
PET scans were reported only as positive or negative by IHP
criteria.18 PET score was not used to stratify patients, and it
is unknown whether patients with a score of 5 were bal-
anced between treatment arms. We propose using a score
of 5 as a basis for treatment escalation and/or as a strati-
fication factor in future PET-adapted trials.
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FIG 3. Kaplan-Meier curves of event-free survival (EFS) by (A) European Organisation for Research and Treatment of Cancer (EORTC) and (B) German
Hodgkin Study Group (GHSG) risk group.
TABLE 4. EFS and PFS by Individual Clinical Risk Factors
Comparison
EFS PFS
HR (95% CI) P HR (95% CI) P
Age $ 50 years 1.16 (0.59 to 2.31) .66 2.15 (1.24 to 3.70) .01
Male v female sex 1.77 (0.95 to 3.30) .07 1.73 (0.99 to 3.02) .05
Stage II v I 1.19 (0.62 to 2.28) .60 0.87 (0.51 to 1.52) .63
ESR $ 50 0.77 (0.27 to 2.16) .61 0.94 (0.40 to 2.21) .89
Nonmediastinal bulk 2.42 (0.33 to 17.58) .38 1.92 (0.26 to 13.86) .52
Extranodal disease Not estimable Not estimable
No. of involved nodal sites
$ 3 1.17 (0.63 to 2.18) .62 1.10 (0.63 to 1.94) .73
$ 4 0.92 (0.33 to 2.58) .88 0.93 (0.37 to 2.33) .87
Abbreviations: EFS, event-free survival; ESR, erythrocyte sedimentation rate; HR, hazard ratio; PFS, progression-free survival.
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The PET scoring system used here and in other UK NCRI
trials29 evolved directly into the 5-point Deauville scale.15 A PET
score of 5 is defined as three times the maximum liver uptake
in UK NCRI-led trials. The Lymphoma Study Association and
Fondazione Italiana Linfomi use the lower threshold of twice the
maximum liver uptake. Improvements in imaging technology,
especially new reconstruction algorithms, mean that today,
PET is more sensitive, and there may be a shift toward more
scans being scored as 3 or 4.31 Treatment efficacy may also
affect the predictive ability of PET.32 Quantitative PET(qPET),
which is a ratio between residual FDG and mean liver uptake,
replaces an ordinal with a continuous scale and may help to
refine the threshold between adequate and inadequate re-
sponse for treatment optimization and allow individualized risk
estimates in the future.33,34
In RAPID, neither GHSG nor EORTC risk score was as-
sociated with outcomes. Unlike most early-stage HL
studies, treatment in RAPID was not adapted according to
baseline risk, and this is one of the first studies to explore
the prognostic relevance of clinical risk stratification in the
context of PET-adapted treatment. Given the much
stronger association with PET score, our findings suggest
that pretreatment risk stratification may have diminished
relevance with PET-adapted treatment, particularly for
patients without mediastinal bulk or B symptoms. It is
unclear whether our findings are applicable to the wider
early-stage HL population, particularly patients with me-
diastinal bulk, who were excluded from RAPID and in
whom the association with adverse outcomes may be
stronger.6 However, all risk factors are weighted equally
within EORTC and GHSG groupings, which are designed to
apply to all patients with early-stage HL, including the
RAPID population; therefore, our findings highlight weak-
nesses in current risk stratification models.
Our results are similar to those of retrospective studies in
advanced-stage HL, where the International Prognostic
Score failed to retain independent prognostic significance
over interim PET assessment.7,35 Indeed, in a subsidiary
analysis of H10, only PET assessment, but not baseline risk
stratification, was prognostic on multivariable analysis,
although treatment was adapted according to EORTC
stratification.28 A subsidiary analysis of the GHSG early-
stage HL trials in the pre-PET era showed a small absolute
difference in PFS between favorable and unfavorable risk
groups for patients treated with ABVD and IFRT (9.4% for
GHSG and 6.7% for EORTC risk stratification).6 These
findings emphasize the need to re-evaluate the use of
clinical prognostic grouping in early-stage HL in the era of
PET-adapted therapy. Incorporation of biological or
baseline PET parameters may be required to improve
pretreatment risk stratification.28,36,37
In conclusion, this subsidiary analysis of the RAPID trial
demonstrates that PET response assessment after che-
motherapy has a much stronger association with out-
comes than clinical risk stratification in early-stage HL. We
have shown that a positive PET scan does not carry
uniform prognostic weight, with only a PET score of 5
associated with inferior outcomes in RAPID; patients with
nonbulky early-stage HL and a PET score of 3 or 4 after
three cycles of ABVD were treated effectively with a fourth
cycle of ABVD and IFRT. In future trials, we propose
reserving treatment escalation with its attendant toxicity in
this patient group for those with a PET score of 5, who
have significantly worse outcomes than those patients
with PET scores of 1 to 4. These results support the
continued development and use of PET-adapted strate-
gies in early-stage HL.
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FIG A1. Kaplan-Meier curves of event-free survival (EFS) by positron emission tomography score (PET) of 1 to 4 versus 5 for (A) EORTC favorable risk, (B)
EORTC unfavorable risk, (C) GHSG favorable risk, and (D) GHSG unfavorable risk.
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TABLE A1. Pretreatment Risk Stratification in Early-Stage HL
Criterion GHSG EORTC
ESR
B symptoms $ 30 $ 30
No B symptoms $ 50 $ 50
No. of involved nodal areas $ 3* $ 4†
Extranodal disease Present
Age, years $ 50
Mediastinal mass $ One third maximum thoracic diameter‡ Mediastinum-to-thorax ratio $ 0.35
NOTE. Patients with stage I or II Hodgkin lymphoma (HL) are classified as having unfavorable risk disease if any one of these adverse risk
factors listed is present.
Abbreviations: EORTC, European Organisation for Research and Treatment of Cancer; ESR, erythrocyte sedimentation rate; GHSG, German
Hodgkin Study Group.
*Of 11 GHSG nodal areas.
†Of five supradiaphragmatic EORTC nodal areas.
‡Patients with stage IIB disease and mediastinal mass and/or extranodal disease are treated as having advanced-stage disease by GHSG
criteria.
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TABLE A2. Baseline Demographic and Clinical Characteristics by PET Group
(N = 562)
Characteristic
No. (%)
P
PET Score
Total
(N = 562)
1 to 4
(n = 541)
5
(n = 21)
Age, years .53
Median 34 34 34
Range 16-75 18-74 16-75
Age, years .12
, 50 416 (76.9) 13 (61.9) 429 (76.3)
$ 50 125 (23.1) 8 (38.1) 133 (23.7)
Sex .04
Female 254 (47.0) 5 (23.8) 259 (46.1)
Male 287 (53.0) 16 (76.2) 303 (53.9)
Stage .48
IA 180 (33.3) 5 (23.8) 185 (32.9)
IIA 361 (66.7) 16 (76.2) 377 (67.1)
ESR $ 50 (n = 468) 60 (13.4) 1 (5.3) 61 (13.0) .49
Nonmediastinal bulk present 6 (1.1) 0 6 (1.1)
Extranodal disease present 1 (0.2) 0 1 (0.2)
No. of involved nodal sites
$ 3 164 (30.3) 11 (52.4) 175 (31.1) .05
$ 4 53 (9.8) 3 (14.3) 56 (10.0) .46
GHSG criteria (n = 480) .81
Favorable 312 (67.8) 13 (65.0) 325 (67.7)
Unfavorable 148 (32.2) 7 (35.0) 155 (32.3)
Missing 81 1 82
EORTC criteria (n = 492) .25
Favorable 298 (63.1) 10 (50.0) 308 (62.6)
Unfavorable 174 (36.9) 10 (50.0) 184 (37.4)
Missing 69 1 70
Abbreviations: ESR, erythrocyte sedimentation rate; EORTC, European
Organisation for Research and Treatment of Cancer; GHSG, German Hodgkin
Study Group; PET, positron emission tomography.
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